Here, we found that this phenomenon is common to many cancer types driven by EGFR, KRAS, or BRAF mutations in response to multiple, clinically approved MAPK pathway inhibitors. In 2D cultures and 3D ...

A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients.. JCO 37 , 3071-3071 (2019). DOI: 10.1200/JCO.2019.37.15_suppl.3071 ...

Clinical tests of the novel small-molecule inhibitor of p38α MAPK, VX-702, have resulted in an all-too-familiar outcome: modest clinical efficacy and transient inhibition of inflammatory markers.